With the aid of its Emergency Funding Request for Texas Biomed’s Scientific Revolution Capital Campaign, the Institute is successfully responding to COVID-19, and we have a unique opportunity to partner with even more national and international biotechnology and pharmaceutical companies.

Success
- With donor support of more than $5 million, Texas Biomed mobilized to deliver the required animal models in order to test therapy and vaccine candidates against COVID-19.
- Texas Biomed has partnered with three companies whose therapies and vaccines are now in use today — Pfizer, Regeneron and Novavax.
- The Institute has gained national and international recognition for its research and has many pharmaceutical companies waiting in the queue to partner with us.
- With worldwide partners, Texas Biomed researchers established the first suitable nonhuman primate (NHP) and mouse models necessary for testing the safety and efficacy of therapies and vaccines for COVID-19.

Progress and Opportunity
- The national shortage of animal models is recognized as a severe limitation that must be addressed – the availability of an adequate supply of the rhesus macaque NHP model and the space to properly manage and care for the growing colony will impact the speed and efficiency by which future research questions can be addressed, including research into COVID-19 variants, long-term effects of COVID-19 and future therapeutic and vaccine work.
- Texas Biomed has received a commitment of a competitive $4 million Federal Cares Act grant towards construction of a $13.5 million, 45,000 sq. ft. Nonhuman Primate (NHP) Animal Facility (ALFA). This award provides nearly half the funding towards this critical resource.

The Gap
Texas Biomed needs $9.5 million to match this commitment in the next two months in order to receive the federal grant. We are 85% of the way to our goal.

Your Support Makes a Difference
A contribution or pledge today will enable Texas Biomed to provide a national resource in the NHP ALFA project for COVID-19 studies and future infectious disease challenges. You can be a part of life-saving history to move science forward faster because our health starts with science.